GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated May 20, 2024, serves as a transaction notification for the month of May 2024. The document discloses specific share transactions conducted by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with the company.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for GSK Plc. It exclusively reports on individual insider trading activities. The only financial data provided relates to the specific transaction prices and volumes for the individuals listed below:
- Share Price (Ordinary Shares): Approximately £17.87 - £17.88
- Share Price (ADS): $44.88
Material Changes and Transactions
The filing details the following transactions executed on May 16, 2024:
- Sally Jackson (SVP, Global Communications & CEO Office):
- Sold 1,120 Ordinary Shares at £17.88 to facilitate a transfer into an Individual Savings Account (ISA).
- Purchased 1,112 Ordinary Shares at £17.87 into an ISA.
- Dylan Jackson (PCA of Sally Jackson):
- Sold 1,120 Ordinary Shares at £17.87 to facilitate a transfer into an ISA.
- Purchased 1,112 Ordinary Shares at £17.8740 into an ISA.
- Dr. Hal Barron (Non-Executive Director):
- Acquired 61 American Depositary Shares (ADSs) at $44.88 via dividend reinvestment in a 401(k) plan.
- Acquired 2,432.6749 notional ADSs at $44.88 via dividend reinvestment in an Executive Supplemental Savings Plan.
- James Ford (SVP and Group General Counsel):
- Acquired 45.2660 notional ADSs at $44.88 via dividend reinvestment in an Executive Supplemental Savings Plan.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. The document is strictly a regulatory disclosure of insider trading activity.
Investor Verification Checklist
- Verify the total shareholding positions of Sally Jackson, Dylan Jackson, Dr. Hal Barron, and James Ford following these transactions.
- Confirm the nature of the ISA transfers for the Jackson transactions to ensure they align with standard tax-advantaged account movements.
- Review the dividend reinvestment policies for the 401(k) and Executive Supplemental Savings Plans to understand the automatic acquisition of ADSs by Dr. Barron and Mr. Ford.
- Note that this filing contains no operational or financial performance data for the company.